Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.

Cohort studyEye (London, England)· Jul 2026

Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.

Clarissa Ern Hui Fang, Nyaish Mansoor, Kenneth Yau

Read paper

GlaucomaCohort studyTreatmentQ1IF 3.3

Paul Glaucoma Implant kept eye pressure controlled in most children after 5 years

Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.

Clarissa Ern Hui Fang … Kenneth Yau

Eye (London, England) · Jul 2026 · Q1 in Ophthalmology

Background

To evaluate the long-term efficacy and safety of the Paul Glaucoma Implant (Paul Glaucoma Implant) in a paediatric cohort.

Methods

A retrospective review of 113 eyes from 83 paediatric patients (age range 4 months to 18 years, mean 9 ± 5 years) who underwent Paul Glaucoma Implant implantation between June 2019 and April 2024.

n = 113 eyes

81.4%

Results

81.4%

at 5 years, most eyes still had pressure controlled, with or without eye drops

n = 113 eyes

More results

The mean preoperative IOP was 27.2 ± 6.2 mmHg.

The mean number of preoperative medications was 3.8 ± 0.8.

Postoperatively, they were 0.9 at 12, 18, and 24 months, 0.7 at 36 months, 1.0 at 48 months, and 0.7 at 60 months (p < 0.001).

More results

Thirty-nine eyes (35%) underwent Prolene stent removal (mean 9.7 months post-op), resulting in further IOP reduction (14.3 mmHg) and medication (0.8).

“

Conclusion

Paul Glaucoma Implant demonstrates sustained IOP reduction, reduced medication burden, and an acceptable safety profile in refractory paediatric glaucoma. It represents an effective long-term surgical option for this challenging cohort.

Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.

Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.

Related papers